Padcev + Keytruda: "Enfortumab vedotin (EV) (3/7): Study data by disease stage of UC"; Urothelial cancer (Astellas) - Apr 27, 2025 - FY 2024 Results: "Statistically significant and clinically meaningful improvement over chemotherapy with nearly doubled mOS and mPFS"
P3 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Urothelial Cancer
|